GSK - Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14
- In the following, I review the recent FDA approval and label for LUPKYNIS and tease out some of the bullish implications.
- I then consider more factors in the comparison to competitor drug Benlysta.
- Finally, I build and justify a DCF model which yields a new price target of $64.25 for AUPH.
For further details see:
Aurinia Pharmaceuticals Is A Better Value Today At $17 Than It Was A Month Ago At $14